BLUEBIRD BIO INC (BLUE)
US09609G1004 - Common Stock
We assign a fundamental rating of 3 out of 10 to BLUE. BLUE was compared to 588 industry peers in the Biotechnology industry. While BLUE seems to be doing ok healthwise, there are quite some concerns on its profitability. BLUE is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year BLUE has reported negative net income.
BLUE had a negative operating cash flow in the past year.
In the past 5 years BLUE always reported negative net income.
In the past 5 years BLUE always reported negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of -14.86%, BLUE belongs to the best of the industry, outperforming 86.69% of the companies in the same industry.
The Return On Equity of BLUE (-40.99%) is better than 74.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.86% | ||
| ROE | -40.99% | ||
| ROIC | N/A |
ROA(3y)-73.59%
ROA(5y)-58.25%
ROE(3y)-133.46%
ROE(5y)-98.26%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BLUE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BLUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BLUE has been increased compared to 1 year ago.
Compared to 5 years ago, BLUE has more shares outstanding
There is no outstanding debt for BLUE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -10.69, we must say that BLUE is in the distress zone and has some risk of bankruptcy.
BLUE's Altman-Z score of -10.69 is on the low side compared to the rest of the industry. BLUE is outperformed by 79.01% of its industry peers.
BLUE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.69 |
ROIC/WACCN/A
WACC9.22%
2.3 Liquidity
A Current Ratio of 1.55 indicates that BLUE should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.55, BLUE is doing worse than 82.08% of the companies in the same industry.
A Quick Ratio of 1.42 indicates that BLUE should not have too much problems paying its short term obligations.
BLUE has a worse Quick ratio (1.42) than 83.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.55 | ||
| Quick Ratio | 1.42 |
3. Growth
3.1 Past
BLUE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.89%, which is quite impressive.
BLUE shows a strong growth in Revenue. In the last year, the Revenue has grown by 327.45%.
The Revenue for BLUE have been decreasing by -36.70% on average. This is quite bad
EPS 1Y (TTM)67.89%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q29.79%
Revenue 1Y (TTM)327.45%
Revenue growth 3YN/A
Revenue growth 5Y-36.7%
Revenue growth Q2Q12300%
3.2 Future
BLUE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.15% yearly.
Based on estimates for the next years, BLUE will show a very strong growth in Revenue. The Revenue will grow by 63.00% on average per year.
EPS Next Y61.68%
EPS Next 2Y28.43%
EPS Next 3Y21.49%
EPS Next 5Y14.15%
Revenue Next Year-6.01%
Revenue Next 2Y80.26%
Revenue Next 3Y90.42%
Revenue Next 5Y63%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BLUE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BLUE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BLUE's earnings are expected to grow with 21.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.43%
EPS Next 3Y21.49%
5. Dividend
5.1 Amount
No dividends for BLUE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BLUEBIRD BIO INC
NASDAQ:BLUE (5/3/2024, 7:00:01 PM)
After market: 0.9199 +0.02 (+2.23%)0.8998
0 (-0.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap171.29M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.86% | ||
| ROE | -40.99% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.55 | ||
| Quick Ratio | 1.42 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)67.89%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y61.68%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)327.45%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y